Kura Oncology, Inc. (KURA) Key Metrics
KURA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $807.8M
- Enterprise value
- $486.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 10.5
- Price / book
- 20.3 10-yr median 2.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.47
KURA key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsKURA valuation Price multiples at each fiscal year-end price.
Price / sales−3.1%
13.5
2025 · hover or tap a bar for each year
20162025
Price / book+188.3%
5.2
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−25.6 pts
−7.8%
2025 · hover or tap a bar for each year
20162025
KURA returns How much profit the business earns on the capital it uses.
Return on equity−51.9 pts
−94.8%
2025 · hover or tap a bar for each year
20162025
Return on assets−8.4 pts
−37.2%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin−353.2 pts
−104.8%
2025 · hover or tap a bar for each year
20162025
Asset turnover+1.0%
0.09
2025 · hover or tap a bar for each year
20162025
KURA per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+23.1%
$0.77
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$3.18
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$0.81
2025 · hover or tap a bar for each year
20162025
Book value per share−58.6%
$1.99
2025 · hover or tap a bar for each year
20162025
Shares outstanding+1.8%
87.7M
2025 · hover or tap a bar for each year
20162025
KURA financial health Debt, liquidity and how easily interest is covered.
Debt / equity+192.8%
0.12
2025 · hover or tap a bar for each year
20162025
Net debt+$64.0M
−$646.8M
2025 · hover or tap a bar for each year
20162025
Current ratio−36.0%
6.06
2025 · hover or tap a bar for each year
20162025
Interest coverage
-200.8
2025 · hover or tap a bar for each year
20162025
Debt / assets+26.9%
0.03
2025 · hover or tap a bar for each year
20162025
KURA efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+20 days
51 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+19,955 days
20,767 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−18,613 days
-19,394 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+9.0 pts
9.8%
2025 · hover or tap a bar for each year
20162025
KURA valuation history
Fiscal year-endToday10-year median
KURA returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
KURA debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
KURA price vs earnings per share
Share price at year-endEPS (right axis)
KURA key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $911.0M | $750.5M | $1.05B | $831.3M | $928.9M | $1.73B | $576.8M | $494.1M | $355.5M | $110.3M |
| Enterprise value | $264.2M | $39.7M | $646.3M | $407.4M | $417.8M | $1.12B | $347.6M | $322.6M | $269.5M | $49.9M |
| Price / sales | 13.5 | 13.9 | — | — | — | — | — | — | — | — |
| Price / book | 5.2 | 1.8 | 2.7 | 2.0 | 1.8 | 2.8 | 2.6 | 3.1 | 4.5 | 1.9 |
| Price / free cash flow | — | 5.6 | — | — | — | — | — | — | — | — |
| Price / operating cash flow | — | 5.6 | — | — | — | — | — | — | — | — |
| EV / sales | 3.9 | 0.7 | — | — | — | — | — | — | — | — |
| EV / free cash flow | — | 0.3 | — | — | — | — | — | — | — | — |
| Earnings yield | −30.6% | −23.2% | −14.5% | −16.3% | −14.0% | −5.2% | −10.9% | −12.2% | −10.0% | −25.0% |
| Free cash flow yield | −7.8% | 17.8% | −11.9% | −13.3% | −11.4% | −4.2% | −9.5% | −9.8% | −8.0% | −23.0% |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $10.39 | $8.71 | $14.38 | $12.41 | $14.00 | $32.66 | $13.75 | $14.04 | $15.30 | $5.90 |
| Per share | ||||||||||
| Revenue per share | $0.77 | $0.63 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$3.18 | −$2.02 | −$2.08 | −$2.03 | −$1.97 | −$1.69 | −$1.51 | −$1.72 | −$1.52 | −$1.47 |
| Operating cash flow per share | −$0.73 | $1.56 | −$1.70 | −$1.64 | −$1.58 | −$1.32 | −$1.31 | −$1.38 | −$1.22 | −$1.36 |
| Free cash flow per share | −$0.81 | $1.55 | −$1.71 | −$1.65 | −$1.59 | −$1.36 | −$1.31 | −$1.38 | −$1.22 | −$1.36 |
| Cash per share | $7.61 | $8.44 | $5.79 | $6.54 | $7.81 | $11.93 | $5.65 | $5.09 | $4.01 | $3.62 |
| Book value per share | $1.99 | $4.80 | $5.43 | $6.27 | $7.64 | $11.51 | $5.22 | $4.57 | $3.44 | $3.04 |
| Tangible book value per share | $1.99 | $4.80 | $5.43 | $6.27 | $7.64 | $11.51 | $5.22 | $4.57 | $3.44 | $3.04 |
| Capex per share | $0.08 | $0.01 | $0.00 | $0.01 | $0.02 | $0.04 | $0.05 | $0.06 | $0.09 | $0.00 |
| Debt per share | $0.23 | $0.19 | $0.23 | $0.21 | $0.10 | $0.28 | $0.18 | $0.21 | $0.31 | $0.39 |
| Shares outstanding | 87.7M | 86.2M | 73.2M | 67.0M | 66.4M | 53.1M | 41.9M | 35.2M | 23.2M | 18.7M |
| Change in shares outstanding | +1.8% | +17.7% | +9.3% | +1.0% | +25.0% | +26.5% | +19.2% | +51.4% | +24.3% | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −94.8% | −42.9% | −37.3% | −29.3% | −23.3% | −21.6% | −33.3% | −50.2% | −51.8% | −39.7% |
| Return on assets (ROA) | −37.2% | −28.8% | −33.7% | −27.4% | −22.1% | −20.2% | −29.8% | −43.5% | −42.8% | −35.1% |
| Return on tangible assets | −37.7% | −22.9% | −34.0% | −29.8% | −24.4% | −13.8% | −26.1% | −33.1% | −37.0% | −39.5% |
| Free cash flow margin | −104.8% | 248.4% | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $20.5M | $16.6M | $17.2M | $14.0M | $6.9M | $15.0M | $7.8M | $7.5M | $7.1M | $7.3M |
| Cash & short-term investments | $667.2M | $727.4M | $424.0M | $438.0M | $518.0M | $633.3M | $236.9M | $179.0M | $93.1M | $67.8M |
| Net debt | −$646.8M | −$710.8M | −$406.8M | −$424.0M | −$511.1M | −$618.3M | −$229.1M | −$171.5M | −$86.0M | −$60.5M |
| Debt / equity | 0.12 | 0.04 | 0.04 | 0.03 | 0.01 | 0.02 | 0.04 | 0.05 | 0.09 | 0.13 |
| Debt / assets | 0.03 | 0.02 | 0.04 | 0.03 | 0.01 | 0.02 | 0.03 | 0.04 | 0.07 | 0.10 |
| Current ratio | 6.06 | 9.46 | 12.26 | 18.56 | 23.26 | 24.49 | 15.39 | 13.31 | 9.43 | 12.62 |
| Quick ratio | 6.05 | 9.46 | 12.26 | 18.56 | 23.26 | 24.49 | 15.39 | 13.31 | 9.43 | 12.62 |
| Interest coverage | -200.8 | -119.3 | -107.0 | -610.8 | -317.0 | -159.0 | -116.3 | -64.8 | -40.6 | -49.2 |
| Working capital | $591.7M | $666.1M | $397.2M | $422.4M | $499.8M | $611.3M | $224.0M | $167.6M | $84.6M | $63.4M |
| Invested capital | −$472.6M | −$297.2M | −$9.5M | −$3.7M | −$4.5M | −$7.4M | −$10.4M | −$10.5M | −$6.2M | −$3.6M |
| Tangible asset value | $174.1M | $413.6M | $397.3M | $420.3M | $506.6M | $610.9M | $218.8M | $161.0M | $79.9M | $56.9M |
| Net current asset value | $144.4M | $398.3M | $380.8M | $410.4M | $494.8M | $601.0M | $216.4M | $159.8M | $78.7M | $55.9M |
| Graham net-net per share | $1.29 | $4.47 | $5.11 | $6.01 | $7.41 | $11.25 | $5.10 | $4.48 | $3.33 | $2.94 |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | $0 | — | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 9.8% | 0.9% | — | — | — | — | — | — | — | — |
| Capex / operating cash flow | — | 0.4% | — | — | — | — | — | — | — | — |
| Capex / depreciation | 6.43 | 0.56 | 0.20 | 0.82 | 2.06 | 11.19 | 217.10 | 217.10 | 72.37 | 0.00 |
| Stock-based compensation / revenue | 55.0% | 62.9% | — | — | — | — | — | — | — | — |
| R&D / revenue | 372.1% | 315.4% | — | — | — | — | — | — | — | — |
| SG&A / revenue | 177.8% | 143.1% | — | — | — | — | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 50.6 | 30.1 | — | — | — | — | — | — | — | — |
| Days of inventory on hand | 1,322.3 | — | — | — | — | — | — | — | — | — |
| Days payables outstanding | 20,766.6 | 811.1 | 823.9 | 1,146.7 | 1,958.8 | 5,906.8 | — | 94,589.8 | 16,157.3 | 13,752.3 |
| Cash conversion cycle (days) | -19,393.7 | -781.0 | — | — | — | — | — | — | — | — |
| Receivables turnover | 7.22 | 12.11 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.02 | 0.45 | 0.44 | 0.32 | 0.19 | 0.06 | — | 0.00 | 0.02 | 0.03 |
| Inventory turnover | 0.28 | — | — | — | — | — | — | — | — | — |
| Asset turnover | 0.09 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $9.4M | $4.5M | $1.9M | $1.1M | $1.4M | — | $127,000 | $220,000 | $255,500 | $362,500 |
| Average payables | $3.2M | $1.9M | $1.9M | $2.4M | $3.0M | $3.1M | $3.7M | $2.6M | $1.3M | $1.2M |
| Average inventory | $206,500 | $0 | — | — | — | — | — | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from KURA's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
KURA valuation and financial ratios
Kura Oncology earned a return on equity of −94.8% in fiscal 2025. It ended the year with $20.5 million of debt and $667.2 million in cash and short-term investments, a net cash position of $646.8 million. The share count rose 368.8% from 18.7M to 87.7M over 9 years.
See the KURA income statement, the KURA chart for price history, or the KURA stock overview for the latest quote and news.
KURA key metrics FAQ
What is Kura Oncology's return on equity?
Kura Oncology's return on equity (ROE) was −94.8% in fiscal 2025: net income of -$278.7 million on average shareholders' equity of $293.9 million.
How much debt does Kura Oncology have?
Kura Oncology had total debt of $20.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.12 and more cash than debt.
What is Kura Oncology's free cash flow yield?
Kura Oncology generated -$70.7 million of free cash flow in fiscal 2025, a free cash flow yield of −7.8% on its market value at year-end ($911.0 million).
What is Kura Oncology's current ratio?
Kura Oncology's current ratio was 6.06 at the end of fiscal 2025: current assets were 6.06 times current liabilities.